Our results confirm the role of NOS3-rs3918226T as a marker of susceptibility for CAD (Nikpay et al., 2015; Van Der Harst and Verweij, 2018; Zhou et al., 2018; Aragam et al., 2022; Temprano-Sagrera et al., 2022) and CVD (Kichaev et al., 2019), plus NOS3-rs891511A as a potential reducer of blood pressure (Liu et al., 2016; Hoffmann et al., 2017; Wain et al., 2017; Feitosa et al., 2018; Sung et al., 2018; Kichaev et al., 2019; Giri et al., 2019; Wojcik et al., 2019; Sakaue et al., 2021; Plotnikov et al., 2022; Schoeler et al., 2023). This evidence concerns the gene NOS3 and coronary artery disorder.